

Biotechnology, Stem Cell and Molecular Diagnostics

April 16-17, 2018
Amsterdam, Netherlands

Mark Engelman et al., Biochem Mol Biol J 2018 Volume: 4
DOI: 10.21767/2471-8084-C2-011

COPYRIGHT IN GENE SEQUENCES

Mark Engelman and Michael Kock

Head of Intellectual Property, Hardwicke Chambers, Research Associate in IP University of Cambridge, UK, Legal Correspondent The Pharma Letter, Director MRG & Associates Ltd
Head of Intellectual Property, Syngenta AG

A discussion concerning the legal recognition of copyright rather than patent in DNA nucleotide sequences as they relate to Mechano growth factor. A discussion of Emergent Genetics India Pvt. Ltd V Shailendra Shivam, Ravindra. With this case we finally have a ruling on the interesting debate on copyrightability of DNA sequences which had been brewing for some time.

Keywords— copyright, DNA Sequences, intellectual property

Biography

Mark Engelman is a pharmacologist (King's Lond.), trained as a barrister. Having practiced with in 2 firms of IP specialist solicitors, 2 major multinationals, he is head of IP at Hardwicke, a set of barristers. He has been non-executive directors of companies which include Alexander McQueen and the patent owner of the Mechano Growth Factor suit of patents. He acts for numerous multinationals. He is a Research Associate at St Edmunds College Cambridge in IP and Bencher of the Hon Soc. of Gray's Inn, London. He is the legal correspondent for The Pharma Letter

mark.engelman@hardwicke.co.uk